Table 2.
Outcome of patients with malignant nodules
| Age (Yr) | Sex (F/M) | Cytology Bethesda | Pathology | Mutation/ Rearrangement | Date of surgery | Initial treatment (surgery, RAI) | pTNM | ATA status at 9–12 months | Additional treatment (surgery, RAI, other) | Date of last visit | ATA status at last visit |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 | F | III | HCC | PAX8/PPARγ | Jul-2015 | TT, RAI | pT2NxM0 | ER | None | Jan-2020 | ER |
| 32 | F | III | FVPTC | NRAS/KRAS | Feb-2015 | TT + CND, RAI | pT1bN1aM0 | IR | None | Jun-2017 | ER |
| 54 | F | IV | HCC | PAX8/PPARγ | Dec-2013 | TT (2), RAI | pT3NxM0 | ER | None | Feb-2020 | ER |
| 49 | F | IV | Classic PTC | BRAF | Jan-2014 | TT (2), RAI | pT2mNxM0 | ER | None | May-2019 | ER |
| 64 | F | IV | PDTC | NRAS | Jan-2015 | TT (2), RAI | pT3mNxM0 | IR | −1st reintervention for LN recurrence in Jan-2018–2nd reintervention for LN and subcutaneous recurrence in Jan-2020 | Feb-2020 | SIR |
| 42 | F | IV | Classic PTC | BRAF | May-2015 | TT + CND | pT1bN0M0 | ER | None | Dec-2019 | IR |
| 37 | F | IV | FTC minimal invasion | NRAS | Sep-2015 | TT (2), RAI | pT3NxM0 | ER | None | Oct-2018 | ER |
| 51 | M | V | Classic PTC | BRAF | Oct-2013 | TT + CND, RAI | pT4aN1aM0 | SIR | Neck and mediastinum external irradiation in Jun-2014 | Feb-2020 | ER |
| 49 | F | V | Classic PTC | BRAF | Feb-2014 | TT(2) + CND, RAI | pT2 N1a M0 | IR | None | Feb-2020 | IR |
| 47 | F | III | PDTC | WT | Jun-2013 | TT(2) + CND, RAI | pT3N0M0 | ER | None | Feb-2020 | ER |
| 63 | F | III | FVPTC | WT | Mar-2015 | TT(2), RAI | pT2NxM0 | ER | None | May-2019 | ER |
| 39 | F | IV | Diffuse sclerosing PTC | WT | Jun-2014 | TT + CND, RAI | pT3N1aM0 | IR | None | Mar-2019 | ER |
| 68 | M | IV | PDTC | WT | Mar-2014 | TT, RAI | pT3NxM0 | IR | 2nd RAI treatment for Tg increase in Dec-2019 | Dec-2019 | SIR |
| 83 | M | IV | PDTC | WT | Mar-2014 | TT (2), RAI | pT2NxM0 | ER | None | Feb-2020 | ER |
| 36 | F | IV | HCC | WT | Mar-2015 | TT(2) + CND | pT2N0M0 | ER | None | Mar-2019 | ER |
| 36 | F | IV | FTC minimal invasion | WT | Jun-2015 | TT(2), RAI | pT2NxM0 | IR | None | Mar-2020 | ER |
| 76 | F | V | FVPTC | WT | Jan-2014 | TT | pT2NxM0 | IR | None | Apr-2018 | IR |
| 59 | F | V | Oncocytic PTC | WT | Jul-2014 | TT | pT1aN0M0 | IR | None | Oct-2015 | IR |
| 80 | F | V | PDTC | WT | Oct-2014 | TT + CND, RAI | pT3N0M0 | BIR | None | Dec-2017 |
Deatha BIR |
WT wild-type, PTC papillary thyroid cancer, FVPTC PTC with follicular variant, FTC follicular thyroid carcinoma, HCC Hürthle-cell carcinoma, PDTC poorly differentiated thyroid carcinoma, TT total thyroidectomy, TT (2) total thyroidectomy in two times, CND central neck dissection, RAI radioiodine treatment, ER excellent response, IR indeterminate response, BIR biochemical incomplete response, SIR structural incomplete response
aThe patient died of metastatic colic carcinoma and presented with evidence of BIR just before